Uncertainty management for In Silico screening of reversed-phase liquid chromatography methods for small compounds.

Method development Multi-criteria decision analysis Response surface methodology Reversed-phase liquid chromatography Small pharmaceutical compounds

Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
20 Jul 2024
Historique:
received: 21 05 2024
revised: 18 07 2024
accepted: 18 07 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 24 7 2024
Statut: aheadofprint

Résumé

The process of developing new reversed-phase liquid chromatography methods can be both time-consuming and challenging. To meet this challenge, statistics-based strategies have emerged as cost-effective, efficient and flexible solutions. In the present study, we use a Bayesian response surface methodology, which takes advantage of the knowledge of the pKa values of the compounds present in the analyzed sample to model their retention behavior. A multi-criteria decision analysis (MCDA) was then developed to exploit the uncertainty information inherent in the model distributions. This strategic approach is designed to integrate seamlessly with quantitative structure retention relationship (QSRR) models, forming an initial in-silico screening phase. Of the two methods presented for MCDA, one showed promising results. The method development process was carried out with the optimization phase, generating a design space that corroborates the results of the selection phase.

Identifiants

pubmed: 39047465
pii: S0731-7085(24)00413-8
doi: 10.1016/j.jpba.2024.116373
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116373

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Laboratory for the Analysis of Medicines & Laboratory of Pharmaceutical Analytical Chemistry reports financial support was provided by Fund for Scientific Research. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Thomas Van Laethem (T)

Laboratory for the Analysis of Medicines, University of Liège (ULiège), CIRM, Liège 4000, Belgium; Laboratory of Pharmaceutical Analytical Chemistry, University of Liège (ULiège), CIRM, Liège 4000, Belgium. Electronic address: tvanlaethem@uliege.be.

Priyanka Kumari (P)

Laboratory for the Analysis of Medicines, University of Liège (ULiège), CIRM, Liège 4000, Belgium; Laboratory of Pharmaceutical Analytical Chemistry, University of Liège (ULiège), CIRM, Liège 4000, Belgium.

Bruno Boulanger (B)

Pharmalex Belgium, Mont-Saint-Guibert 1435, Belgium.

Philippe Hubert (P)

Laboratory of Pharmaceutical Analytical Chemistry, University of Liège (ULiège), CIRM, Liège 4000, Belgium.

Marianne Fillet (M)

Laboratory for the Analysis of Medicines, University of Liège (ULiège), CIRM, Liège 4000, Belgium.

Pierre-Yves Sacré (PY)

Laboratory of Pharmaceutical Analytical Chemistry, University of Liège (ULiège), CIRM, Liège 4000, Belgium.

Cédric Hubert (C)

Laboratory of Pharmaceutical Analytical Chemistry, University of Liège (ULiège), CIRM, Liège 4000, Belgium. Electronic address: chubert@uliege.be.

Classifications MeSH